Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Syed Mahmood

Showing results (151-160 of 153) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 153 results.
Ebiomedicine|October 30, 2025
Safety and efficacy of intratumourally administered INT230-6 in adult patients with advanced solid tumours: results from an open-label phase 1/2 dose escalation studyJacob S Thomas, Lillian L Siu, Matthew Ingham, et al.
Ophthalmology|September 22, 2010
Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) studyQuan Dong Nguyen, Syed Mahmood Shah, Afsheen A Khwaja, et al.
American Journal of Ophthalmology|June 13, 2024
Phase 1/2 AAV5-hRKp.RPGR (Botaretigene Sparoparvovec) Gene Therapy: Safety and Efficacy in RPGR-Associated X-Linked Retinitis PigmentosaMichel Michaelides, Cagri G Besirli, Yesa Yang, et al.
Pageof 16

Showing results (151-160 of 153) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 153 results.
Ebiomedicine|October 30, 2025
Safety and efficacy of intratumourally administered INT230-6 in adult patients with advanced solid tumours: results from an open-label phase 1/2 dose escalation studyJacob S Thomas, Lillian L Siu, Matthew Ingham, et al.
Ophthalmology|September 22, 2010
Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) studyQuan Dong Nguyen, Syed Mahmood Shah, Afsheen A Khwaja, et al.
American Journal of Ophthalmology|June 13, 2024
Phase 1/2 AAV5-hRKp.RPGR (Botaretigene Sparoparvovec) Gene Therapy: Safety and Efficacy in RPGR-Associated X-Linked Retinitis PigmentosaMichel Michaelides, Cagri G Besirli, Yesa Yang, et al.
Pageof 16